Fundamentals of population pharmacokinetic modelling: Modelling and software

Clinical Pharmacokinetics

Volumn 51, Issue 8, 2012, Pages 515-525

  Kiang, Tony K L ^a   Sherwin, Catherine M T ^b   Spigarelli, Michael G ^b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

computer software; pharmacokinetic modelling; pharmacokinetics; population pharmacokinetics

Indexed keywords

ACCURACY; ALGORITHM; ARTICLE; BAYES THEOREM; CLINICAL PHARMACOLOGY; COMPARATIVE STUDY; COMPUTER INTERFACE; COMPUTER MODEL; COMPUTER PROGRAM; CONSUMER; DATA ANALYSIS; DATA BASE; DRUG DISPOSITION; EVALUATION; HUMAN; NONLINEAR SYSTEM; PHARMACOKINETICS; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; STANDARDIZATION;

HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NONLINEAR DYNAMICS; PHARMACOKINETICS; SOFTWARE;

EID: 84863500633     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11634080-000000000-00000     Document Type: Article

References (23)

1. Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Monit 1993; 15: 380-93 (Pubitemid 23297240)
2. FDA. Guidance for industry: population pharmacokinetics. US Department of Health and Human Services; Food and Drug Administration; Centre for Drug Evaluation and Research & Centre for Biologics Evaluation and Research, 1999 Feb; CP 1 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf?utm-campaign= Google2&utm-source=fdaSearch&utm-me dium=website&utm-erm=Guidance for industry population pharmaco kinetics&utm-content=1 [Accessed 2011 Sep 1]
3. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38: 1702-6 (Pubitemid 39297771)
4. Shen D, Lu Z. Population pharmacokinetics studies with nonlinear mixed effects modeling. SAS Global Forum 2007 [online]. Available from URL: http://www2.sas.com/proceedings/forum2007/148-2007.pdf [Accessed 2011 Aug 2]
5. Jelliffe RW. Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy [online]. Available from URL: http://www.lapk.org/pubsinfo/pdf/DOX-Tech- Rep-2012-1-4-2-12.pdf [Accessed 2011 Aug 2]
6. D'Argenio DZ. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 1981; 9: 739-56 (Pubitemid 12184821)
7. Jelliffe RW, Gomis P, Schumitzky A. A population model of gentamicin made with a new nonparametric EM algorithm. Los Angeles (CA): Laboratory of Applied Pharmacokinetics, USC School of Medicine, 1990. Technical report no.: 90-4
8. Concordet D, Léger F, Ané C. Population PK/PD analysis. In: Chow S, editor. Encyclopedia of biopharmaceutical statistics. New York: Marcel Dekker, Inc., 2004
9. Bustad A, Terziivanov D, Leary R, et al. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 2006; 45: 365-83
10. Jelliffe R, Schumitzky A, Van Guilder M. Population pharmacokinetics/ pharmacodynamics modeling: parametric and nonparametric methods. Ther Drug Monit 2000; 22: 354-65 (Pubitemid 30346454)
11. Ogungbenro K, Aarons L. Design of population pharmacokinetic experiments using prior information. Xenobiotica 2007; 37: 1311-30 (Pubitemid 350035531)
12. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-43 (Pubitemid 351367434)
13. Dartois C, Brendel K, Comets E, et al. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol 2007; 64: 603-12 (Pubitemid 47568828)
14. Pillai GC, Mentre F, Steimer JL. Non-linear mixed effects modeling-from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn 2005; 32: 161-83 (Pubitemid 41712738)
15. Aarons L. Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1999; 36: 255-64 (Pubitemid 29201734)
16. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83
17. Machado SG, Miller R, Hu C. A regulatory perspective on pharmacokinetic/pharmacodynamic modelling. Stat Methods Med Res 1999; 8: 217-45 (Pubitemid 30005354)
18. Aarons L, Balant LP, Mentre F, et al. Population approaches in drug development: report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software. Eur J Clin Pharmacol 1994; 46: 389-91 (Pubitemid 24199196)
19. Buffington DE, Lampasona V, Chandler MH. Computers in pharmacokinetics: choosing software for clinical decision making. Clin Pharmacokinet 1993; 25: 205-16 (Pubitemid 23262171)
20. Charles BG, Duffull SB. Pharmacokinetic software for the health sciences: choosing the right package for teaching purposes. Clin Pharmacokinet 2001; 40: 395-403 (Pubitemid 32656076)
21. Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907-15 (Pubitemid 39425727)
22. Dartois C, Lemenuel-Diot A, Laveille C, et al. Evaluation of uncertainty parameters estimated by different population PK software and methods. J Pharmacokinet Pharmacodyn 2007; 34: 289-311 (Pubitemid 46873028)
23. Beal SL, Sheiner LB. The NONMEM system. Am Stat 1980; 34: 118-9